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Abstract
Objective—To determine factors regulating human aortic smooth muscle cells (HASMC)
supported tissue factor-induced thrombin generation.
Methods and Results—The addition of nonlipidated tissue factor and Ca2+ to HASMCs
maintained in reptilase-treated platelet-poor plasma resulted in the robust formation of thrombin
after a lag phase of approximately 6 minutes. Pretreatment with low concentrations of α-thrombin
before the addition of tissue factor and Ca2+ accelerated the rate of thrombin generation (time to
reach half of peak thrombin was reduced by [mean±SD] 42.0±2.2%; P<0.05) but had no effect on
the amount of peak thrombin generated. Protease-activated receptor (PAR) 3 activating peptides
(APs) or PAR-4 APs accelerated thrombin generation without affecting peak thrombin levels
(time to half of peak thrombin decreased by 17.4±5.6% and 21.7±3.5%; P<0.05 with PAR-3 AP
and PAR-4 AP, respectively). The addition of PAR-3 AP and PAR-4 AP together had an additive
effect, with a reduction in time to half of peak thrombin of 43.9±4.0%. PAR-3 AP or PAR-4 AP
enhanced tissue factor–induced factor Xa production and phosphatidylserine exposure on the
surface of HASMCs. PAR-1 activation had no effect on thrombin generation, factor Xa
production, or phosphatidylserine exposure.
Conclusion—Low concentrations of α-thrombin accelerate tissue factor–induced thrombin
generation on the surface of HASMCs, and this effect is mediated by PAR-3 and PAR-4.
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Cardiovascular disease resulting from the formation of an arterial thrombus remains a
leading cause of mortality and morbidity in the Western world. Advances in anticoagulant
and antiplatelet therapies have reduced cardiovascular events during acute coronary
syndromes and percutaneous coronary interventions, yet thrombotic events still occur
despite treatment with the most potent inhibitors of the coagulation system that are
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available.1 In addition, recent studies have highlighted the important adverse impact of
bleeding complications on clinical outcomes, providing more impetus for an understanding
of optimal anticoagulation at the site of vascular injury.2
Arterial injury that disrupts the endothelium at sites of atherosclerotic plaques enables
plasma to come into contact with tissue factor–bearing cells.3,4 This results in the production
of small amounts of thrombin with virtually little or no platelet participation, a reaction
described as the initiation phase of coagulation.5,6 This small amount of thrombin is crucial
in regulating the coagulation response by controlling the timing and magnitude of further
thrombin production during the priming and propagation phase. Previous results showed that
thrombin generation occurs on the surface of human aortic smooth muscle cells (HASMCs)
after treatment with tissue factor and Ca2+; however, factors that regulate the kinetics of
thrombin generation within the initiation phase are largely unknown.7
Studies in platelets found that activation of protease-activated receptor (PAR) 4, but not
PAR-1, reduced time to peak thrombin without affecting maximal thrombin generated.8
Other studies found that activation of PAR-4 caused a left shift in the dose-response curve of
collagen-induced thrombin generation, providing further evidence that PAR-4 plays a role in
regulating platelet thrombin generation.9 HASMCs express functionally active PAR-1,
PAR-3, and PAR-410,11; however, studies on the role of PARs in SMCs have focused
primarily on contraction and growth responses,12,13 with little information on the role of
PARs in SMC-supported thrombin generation. Because the rate at which thrombin is
generated on the surface of vascular SMCs at arterial injury plays an important role in
vascular thrombosis and arterial repair, the objective of these studies was to examine the
hypothesis that PARs regulate the kinetics of tissue factor–induced thrombin generation in
HASMCs.
Methods
Thrombin and Factor Xa Assays
Thrombin generation was assayed as previously described.7 Briefly, HASMCs from passage
5 to 7 were grown in 24-well tissue culture plates in Dulbecco-modified Eagle medium
supplemented with 10% FCS, 1% penicillin-streptomycin, and SMC proliferation medium at
a seeding density of 8×103 to 10×103 cells/cm2. After reaching 70% to 80% confluence,
HASMCs were washed with ×1 PBS followed by the addition of 500 µL of reptilase-treated
platelet-poor plasma (PPP) per well for 1.5 hours. Fresh-frozen PPP was obtained from the
New York Blood Center and was prepared within 3 hours from fresh blood collected from
healthy voluntary donors; this blood was anticoagulated with sodium citrate, centrifuged at
2000 rpm for 10 minutes at 22°C, centrifuged again at 5000 rpm for 10 minutes at 4°C, and
then frozen at −20°C. Nonlipidated recombinant tissue factor (final concentration, 0.6 pmol/
L) and Ca2+ (final concentration, 0.5 mmol/L) were added. At various points, 15 µL of
plasma from each well was added to 90 µL of 3.8% sodium citrate in 96-well plates and was
used as a stop solution. Thrombin and factor Xa were measured using the chromogenic
substrates S-2238 and S-2765, respectively. Standard curves were generated using known
amounts of thrombin and factor Xa. Factor X–deficient PPP was obtained commercially.
Phosphatidylserine Exposure
Phosphatidylserine (PS) on the surface of HASMCs was detected using a commercially
available fluorescein isothiocyanate kit (Annexin V), as described by Siow et al.14 Images
were captured using a Leica DM Inverted Microscope and the level of fluorescence was
quantified using open source image analysis software (ImageJ; available at:
http://rsbweb.nih.gov/ij/).
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PAR-3 Small and Interfering RNA Transfection
HASMCs were plated at the seeding density of 0.1×106 in 12-well plates and grown
overnight in antibiotic-free complete medium at 37°C with 5% CO2. A total of 50 µL of 2
µmol/L PAR-3 specific siRNA (On-TARGETplus) or scrambled siRNA were added to each
well together with 1.0 µL of the transfection agent (DharmaFECT) in serum-free medium.
The cells were incubated with antibiotic-free complete medium for 24 hours at 37°C with
5% CO2 and then reinfected every 24 hours for 7 days. Western blotting was performed as
previously described.15
Reagents
α-Thrombin, δ-thrombin, and factor Xa were purchased from Hematologic Technologies,
Inc. PAR-1–activating peptide (AP) (SFLLRN-NH2), PAR-2 AP (SLIGRL-NH2), and
PAR-1 antagonist (N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-
f]quinazoline-1,3-diamine dihydrochloride) were obtained from Tocris Bioscience.
Antibodies directed against PAR-1 (ATAP2), PAR-3, and PAR-4 were purchased from
Santa Cruz Biotechnology, Inc; and PAR-4 antagonist (tcY-NH2) was purchased from
BioTrend. PAR-3 AP (TFRGAP) and PAR-4 AP (GYPGQV) were obtained from BaChem,
Inc; and a scrambled PAR-1 peptide (FSLLRN) was obtained from AnaSpec. A monoclonal
anti–tissue factor–blocking antibody (4509) was purchased from American Diagnostica Inc.
Anti–phosphorylated extracellular signal–regulated kinase (ERK) and anti–ERK antibodies
were obtained from Cell Signaling Technology.
Results
Pretreatment With α-Thrombin Accelerates HASMC-Supported Tissue Factor–Induced
Thrombin Generation, and This Effect Requires the Catalytic Activity of Thrombin
The addition of tissue factor and Ca2+ to a monolayer of HASMCs maintained in reptilase-
treated PPP resulted in robust thrombin generation, as previously described (Figure 1A).
Minimal thrombin was generated in the absence of HASMCs. Previously, it was shown that
platelets and platelet microparticles do not contribute to thrombin generation in this system.7
Treatment with low concentrations of α-thrombin before the addition of tissue factor and
Ca2+ resulted in an increase in the rate of thrombin generation. Time to reach half of peak
thrombin was reduced by 42.0±2.2% with the addition of 1.5 U/mL (10.7 nmol/L) of α-
thrombin (P<0.05; Figure 1B). γ-Thrombin, which lacks the catalytic activity of α-
thrombin, had no effect on the time to reach half of peak thrombin compared with control
(decrease of 1.2±3.2%; P=1.0). The amount of peak thrombin generated was similar among
all 3 groups (117.9±2.0 nmol/L for positive control, 119.4±1.3 nmol/L for α-thrombin, and
117.1±1.5 nmol/L for γ-thrombin; P=0.27; Figure 1C). Data are provided as mean±SD.
HASMCs Express Functionally Active PAR-1, PAR-3, and PAR-4
Because the catalytic domain of thrombin was necessary for thrombin-mediated acceleration
of tissue factor–induced thrombin generation on the surface of HASMCs, we next sought to
determine which PARs were involved in this response. The HASMCs used in this study
expressed PAR-1, PAR-3, and PAR-4 (Figure 1D). These receptors were functionally active,
as determined by ERK phosphorylation elicited by treatment with APs that mimic the
“tethered ligand” exposed after thrombin cleavage of PAR (SFLLRN, TFRGAP, and
GYPGQV were used as PAR-1, PAR-3, and PAR-4 APs, respectively; Figure 1E). These
results are consistent with prior studies showing that SFLLRN, TFRGAP, and GYPGQV
elicit ERK 1/2 phosphorylation in human vascular SMCs isolated from the saphenous
vein.10,11
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PAR-1 Does Not Mediate α-Thrombin Acceleration of HASMC-Supported Tissue Factor–
Induced Thrombin Generation
PAR-1 is the most widely studied PAR in vascular cells; it mediates growth responses.12,13
Treatment of HASMCs with varying concentrations of PAR-1 AP (SFLLRN) did not alter
the kinetics of thrombin generation (difference in time to half of peak thrombin between
positive control and PAR-1 AP pretreatment was a decrease of 3.7±7.1%; P=0.83; Figure
2A). Antagonism of PAR-1 with the combination of a peptide antagonist (SCH-79797) and
a blocking antibody (ATAP2) at concentrations that prevented PAR-1 AP-induced ERK 1/2
phosphorylation (Figure 2B) did not inhibit α-thrombin–induced acceleration of tissue
factor–induced thrombin generation when compared with control (increase of 1.6±0.8%;
P=0.75; Figure 2C–2E).
Activation of PAR-3 or PAR-4 Causes Acceleration of HASMC-Supported Tissue Factor–
Induced Thrombin Generation
In contrast to the results observed with PAR-1 AP, pretreatment with either PAR-4 AP or
PAR-3 AP reduced the time to half of peak thrombin (decrease of 17.4±5.6% [P<0.05] and
decrease of 21.7±3.5% [P<0.05], respectively; Figure 3A and 3B, respectively). When
PAR-3 and PAR-4 APs were added simultaneously, the time to half of peak thrombin was
reduced more than with either AP alone (decrease of 43.9±4.0%; P<0.05 versus positive
control, PAR-3 AP, or PAR-4 AP). PAR-3 AP, PAR-4 AP, and the combination of PAR-3
AP plus PAR-4 AP had no effect on peak thrombin generated (Figure 3C).
To test the effects of activation of PAR-3 and PAR-4 on thrombin generation in the absence
of tissue factor–dependent events, we studied the kinetics of thrombin generation in
HASMCs treated with exogenous tissue factor plus a tissue factor–blocking monoclonal
antibody (in the absence of exogenous tissue factor). The addition of tissue factor–blocking
antibody resulted in inhibition of tissue factor–induced thrombin generation and inhibition
of PAR-3 AP–and PAR-4 AP–mediated acceleration of thrombin generation (Figure 3D).
The addition of PAR-3 AP and PAR-4 AP in the absence of exogenous tissue factor had no
effect on thrombin generation (Figure 3E).
Simultaneous Inhibition of Both PAR-3 and PAR-4 Is Required to Prolong the Initiation
Phase of Thrombin Generation
A PAR-4 antagonist (tcY-NH2) that successfully inhibited the activity of the receptor in
human platelets16 abolished PAR-4 AP-induced ERK 1/2 phosphorylation in HASMCs
(Figure 4A). Successful inhibition of PAR-3 function with peptide or antibody antagonists in
HASMCs has not been reported. However, inhibition of PAR-3 function in human vascular
cells using an siRNA approach has been successful17; thus, we used this strategy. HASMCs
were transfected with PAR-3–specific siRNA, and Western blotting confirmed successful
knockdown of PAR-3 (Figure 4B). ERK 1/2 phosphorylation provided functional evidence
that levels of PAR-3 were significantly reduced (Figure 4C).
Treatment with a PAR-4 antagonist had no effect on α-thrombin acceleration of HASMC-
supported tissue factor–induced thrombin generation (Figure 4D). Similarly, a marked
reduction in PAR-3 expression using siRNA did not affect the kinetics of HASMC-
supported tissue factor–induced thrombin generation. Time to half of peak thrombin was
11.5±0.3 minutes for HASMC treated with α-thrombin, 12.0±0.4 minutes for HASMC
treated with α-thrombin +PAR-4 antagonist and 11.9±0.4 minutes in HASMC that did not
express PAR-3 receptors treated with α-thrombin (P=0.21 for comparison between groups).
In contrast, the inhibition of both PAR-4 and PAR-3 prevented α-thrombin acceleration of
HASMC-supported tissue factor–induced thrombin generation (Figure 4D). Time to half of
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peak thrombin for PAR-3 knockdown cells treated with PAR-4 antagonist before the
addition of α-thrombin was 15.5±0.5 minutes (P<0.05 versus treatment with α-thrombin).
PAR-3 AP and PAR-4 AP Enhanced Tissue Factor–Induced Factor Xa Production
We next sought to determine whether α-thrombin effects on acceleration of HASMC-
supported tissue factor–induced thrombin generation occurred before or after factor Xa
generation. Pretreatment with low concentrations of α-thrombin or with PAR-3 AP or
PAR-4 AP resulted in an increase in the amount of factor Xa generated compared with
control (increase of 43.1±5.6%, 30.4±6.7%, 27.3±4.5%, and 34.1±8.1% with 1.5 U/mL of
α-thrombin, 200 µmol/L of PAR-3 AP, 200 µmol/L of PAR-4 AP, or 200 µmol/L of both
PAR-3 and PAR-4, respectively; P<0.05 versus control; Figure 5A and 5B). PAR-1 AP did
not affect the amount of factor Xa generated within 33 minutes of exposure to tissue factor
and Ca2+ (decrease of 0.9±5.7%, P=0.88; Figure 5B).
Thrombin is able to cleave some chromogenic substrates used to determine factor Xa levels,
although the substrate (S-2765) used in these experiments is reportedly highly specific for
factor Xa. Evidence that thrombin was not cleaving S-2765 and, thus, giving falsely elevated
levels of factor Xa is provided by data that bivalirudin, which directly binds to the catalytic
site of α-thrombin,9 had no effect on cleavage of S-2765 (Figure 5C) at a concentration
sufficient to completely suppress all tissue factor–induced thrombin activity, as assayed by
cleavage of S-2238 (Figure 5D).
PAR-3 and PAR-4 Activation Enhanced Exposure of PS on the Surface of HASMCs
PS is an anionic aminophospholipid that, when exposed on the cell surface, plays an
essential role in the assembly of coagulation factor complexes, including the tenase and
prothrombinase complexes, necessary for thrombin generation in HASMCs.7,18 Treatment
with α-thrombin, PAR-3 AP, or PAR-4 AP resulted in a marked increase in PS exposure
beginning as early as 3 minutes after treatment (data not shown). When assayed 7 minutes
after treatment, PS levels on the cell surface had increased approximately 300-fold
compared with treatment with vehicle (Figure 6A and 6B). In contrast, treatment with
PAR-1 AP had no effect on PS exposure. These data were consistent from 6 independent
experiments.
PAR-3 and PAR-4 Activation Accelerated Thrombin Generation Downstream of Factor Xa
Production
PS on the cell surface enhances factor Xa binding to factor Va and the formation of the
prothrombinase complex, which is essential for efficient thrombin generation. Thus, we
examined whether PAR-3 and PAR-4 signaling influenced thrombin generation downstream
of factor Xa generation. To study this question, PPP derived from an individual deficient in
factor X was used. Previously, it was shown that thrombin is not generated when factor X–
deficient plasma is used in the current system.7
The addition of purified factor Xa along with tissue factor and Ca2+ to a monolayer of
HASMCs maintained in reptilase-treated PPP that was deficient in factor X resulted in
robust thrombin generation (Figure 7). Treatment with low concentrations of α-thrombin or
PAR-3 AP plus PAR-4 AP resulted in an acceleration of thrombin generation in HASMCs
maintained in factor X–deficient plasma when factor Xa was added at time 0 (Figure 7). In
contrast, PAR-1 AP had no effect on the kinetics of thrombin generation in this system. No
thrombin was generated in the absence of exogenous factor Xa in any of the groups.
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The results of these studies show that tissue factor–induced thrombin generation on the
surface of HASMCs is accelerated by low concentrations of α-thrombin and that this effect
is primarily, if not solely, mediated via PAR-3 and PAR-4. PAR-3 and PAR-4 provide a
redundant pathway in the early phase of thrombin generation in that activation of either
PAR-3 or PAR-4 reduces the time to half of peak thrombin, whereas blockage of the effects
of thrombin on the kinetics of the reaction requires successful inhibition of both receptors.
The biological events responsible for a shift in the kinetics of thrombin generation are
worthy of investigation because the rate of thrombin generation is important for timely
hemostasis and, thus, the mechanisms that dictate the rate of clot formation are of interest in
drug development.
Results observed in HASMCs whereby PAR-3 and PAR-4 independently contribute to
acceleration of thrombin production mimic the redundancy in platelets provided by PAR-1
and PAR-4. Human platelets express PAR-1 and PAR-4 but not PAR-3.19,20 The activation
of either PAR-1 or PAR-4 in human platelets can trigger secretion and aggregation.21
Successful inhibition of thrombin-induced platelet activation required blocking both PAR-1
and PAR-4, whereas inhibition of PAR-4 alone has no impact on platelet activation and
inhibition of PAR-1 was only able to block platelet activation at low thrombin
concentrations.22 Our data in HASMCs showed that activation of either PAR-3 or PAR-4
reduced the time to half of peak thrombin with an additive effect when both receptors were
activated simultaneously. Analogous to the platelet model, inhibition of both PAR-3 and
PAR-4 was required to block α-thrombin–induced acceleration in thrombin generation in
HASMCs.
Potential mechanisms for interactions between different types of PARs on HASMCs are
provided by studies in platelets. Thrombin activates platelets by cleaving PAR-1 and PAR-4,
which signal with different kinetics and appear to have distinct functions in platelet
aggregation. PAR-1 and PAR-4 evoke 2 distinct waves of intracellular calcium in which the
signal from PAR-1 is brief and fast and the signal from PAR-4 is slower in onset but more
prolonged.23 PAR-1 also serves to enhance the response of PAR-4 to thrombin on the
surface of human platelets by forming stable heterodimeric complexes that assist in the
activation and cleavage of PAR-4.24 The effects of interactions of PAR-1 and PAR-4 on
platelet-mediated thrombin generation were reported by Thomas et al,25 who found that
thrombin treatment of human platelets resulted in PAR-1– and PAR-4–dependent
production of phosphatidylethanolamine or phosphatidylcholine-esterified 12S-HETE.
Esterified HETEs remained cell associated, with HETE-phosphatidylethanolamines
migrating to the outside of the plasma membrane, where they enhanced tissue factor–
dependent thrombin generation.
Activation of PAR-3 and PAR-4 increased the amount and rate of tissue factor, and Ca2+
stimulated factor Xa generation on the surface of HASMCs. Furthermore, the effects of
PAR-3 and PAR-4 activation on factor Xa generation were abolished by antibodies against
tissue factor. PAR-3 and PAR-4 signaling also accelerated thrombin generation via
mechanisms downstream of factor Xa generation. These findings are consistent with the
cell-based thrombin generation model proposed by Monroe et al.5 During the initiation
phase of cell-based coagulation, model factor Xa formed by factor VIIa/TF binds to factor
Va on the cell surface and converts a small amount of prothrombin to thrombin. The small
amount of thrombin accelerates further thrombin generation by activation of factor V and
factor VIII. Once activated, factor V moves into a protected complex with factor Xa,
resulting in a burst of thrombin generation, triggering the propagation phase.5 In the current
studies, preincubation with low concentrations of α-thrombin, PAR-3 AP, or PAR-4 AP
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resulted in a faster rate of thrombin generated in the early phase of the reaction without
affecting the amount of peak thrombin generated. Our observations demonstrate that PAR-3
and PAR-4 play a role in the initiation phase of the thrombin generation reaction.
Our data show that α-thrombin, PAR-3 AP, and PAR-4 AP rapidly increase cell surface
expression of PS in HASMCs. Regulation of PS in HASMCs is, thus, different from human
platelets in which externalization of PS is via PAR-1 and inhibition of PAR-1 attenuates PS
expression.26 In HASMCs, PAR-1 AP failed to increase PS exposure and activation of
PAR-1 had no effect on the kinetics of tissue factor–induced thrombin generation. Our
results demonstrate that increased cell surface expression of PS is one mechanism whereby
activation of PAR-3 or PAR-4 could accelerate tissue factor–induced thrombin generation in
HASMCs.
PAR-3 and PAR-4 signaling enhanced thrombin generation both before and after factor Xa
generation, raising the possibility that increased PS expression enhances formation of the
tenase and prothrombinase complexes. Consistent with this hypothesis, Ananyeva et al27
reported that treatment of SMCs with oxidized low-density lipoprotein enhanced PS
translocation to the outer membrane, enhanced tenase and prothrombinase complex activity,
and resulted in a 10-fold increase in thrombin generation and a 6-fold increase in factor Xa
production. Flynn et al18 showed that apoptotic SMCs have increased thrombin generation
activity, which is mediated in part by the translocation of PS from the inner to the outer
leaflet of the cellular membrane. Taken together, these studies show that treatment with
specific agonists (eg, thrombin or oxidized low-density lipoprotein) or apoptosis results in
translocation of PS to the outer surface of SMCs, resulting in enhanced thrombin generation.
The present studies add to the literature on the functional role of PAR-3 and PAR-4 in
SMCs. Bretschneider and colleagues reported that PAR-310 and PAR-411 were expressed on
cultured SMCs from the human saphenous vein and that these receptors mediated calcium
transients and ERK 1/2 phosphorylation. In the current studies, a novel function for PAR-3
and PAR-4 on SMCs has been identified, in which activation of these receptors accelerates
tissue factor–induced thrombin generation.
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Catalytic activity of α-thrombin is required for reduction in time to half of peak thrombin,
and HASMCs express functionally active PAR-1, PAR-3, and PAR-4. HASMCs were
growth arrested, washed, and maintained in reptilase-treated PPP. α-Thrombin or γ-
thrombin (10.7 nmol/L each) was added before the addition of tissue factor and Ca2+.
Experimental wells that were not exposed to any additional treatment served as positive
controls, whereas wells that did not have any cells but that were treated with tissue factor
and Ca2+ served as negative controls. A, A representative experiment. B and C, Results of 4
independent experiments. D, PAR-1, PAR-3, and PAR-4 were detected using specific
monoclonal or polyclonal antibodies, as described in the Methods section. E, Growth-
arrested HASMCs were treated with PAR-1 AP, PAR-3 AP, or PAR-4 AP (200 µmol/L
each); and ERK 1/2 phosphorylation (Phos) was determined 15 minutes later. *P<0.05.
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PAR-1 activation does not affect thrombin generation in HASMCs. HASMCs were growth
arrested, washed, and maintained in reptilase-treated PPP. α-Thrombin (10.7 nmol/L) or
PAR-1 AP (200 µmol/L), with or without PAR-1 antagonists (SCH-79797 plus ATAP-2),
was added. A and C, Tissue factor and Ca2+ were added and thrombin generation was
assayed at the indicated times. Experimental wells that were not exposed to any additional
treatment served as positive controls, whereas wells that did not have any cells but that were
treated with tissue factor and Ca2+ served as negative controls. B, ERK phosphorylation
(pERK) was determined 15 minutes after treatment, as described in the Methods section. A
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through C, Representative data from 4 independent experiments. D and E, The results of 4
independent experiments. *P<0.05.
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Activation of PAR-3 or PAR-4 causes acceleration of HASMC-supported tissue factor–
induced thrombin generation. HASMCs were treated with PAR-3 AP (200 µmol/L), PAR-4
AP (200 µmol/L), PAR-3 AP plus PAR-4 AP, α-thrombin (10.7 nmol/L), or a scrambled
PAR-1 peptide (FSLLRN; 200 µmol/L) for 15 minutes before nonlipidated tissue factor and
Ca2+ were added. Thrombin was assayed at indicated points, as described in the Methods
section. Experimental wells that were not exposed to any additional treatment served as
positive controls, whereas wells that did not have any cells but that were treated with tissue
factor and Ca2+ served as negative controls. A, A representative experiment. B and C, The
results of 4 independent experiments. D, HASMCs were pretreated for 15 minutes with anti–
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tissue factor antibody or nonspecific IgG (1 µg/mL), with or without PAR-3 AP plus PAR-4
AP, before the addition of tissue factor and Ca2+. E, Exogenous tissue factor was only added
to the groups specified in the label. *P<0.05 vs control; there were no statistically significant
differences in the data presented in C.
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Antagonism of both PAR-3 and PAR-4 is required to inhibit the effect of α-thrombin on the
kinetics of tissue factor–induced thrombin (Thr) generation. HASMCs were pretreated with
PAR-4 antagonist (tY-NH2) for 15 minutes before the addition of PAR-1 AP (200 µmol/L),
PAR-3 AP (200 µmol/L), PAR-4 AP (200 µmol/L), or α-thrombin (10.7 nmol/L). A, ERK
phosphorylation (pERK) was determined 15 minutes later. B, HASMCs were transfected
with PAR-3 siRNA or scrambled siRNA, and effective knockdown of PAR-3 was confirmed
with Western blotting performed using a monoclonal antibody directed against PAR-3. C,
These cells were treated with α-thrombin, PAR-1 AP, PAR-3 AP, or PAR-4 AP at the
concentrations indicated; and ERK phosphorylation was determined 15 minutes later.
Transfected cells were treated with vehicle or α-thrombin (10.7 nmol/L), with or without
PAR-4 antagonist (tc-NH2). D, The results of 4 independent experiments. *P<0.05 vs
control (Cnt).
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Activation of PAR-3 or PAR-4 enhances factor Xa production. HASMCs were growth
arrested, washed, and maintained in reptilase-treated PPP. α-Thrombin (10.7 nmol/L),
PAR-1 AP (200 µmol/L), PAR-3 AP (200 µmol/L), or PAR-4 AP (200 µmol/L) was added
15 minutes before the addition of tissue factor and Ca2+. Experimental wells that were not
exposed to any additional treatment served as positive controls, whereas wells that did not
have any cells but that were treated with tissue factor and Ca2+ served as negative controls.
A, A representative experiment. B, The results of 4 independent experiments. C and D,
Bivalirudin (50 µg/mL) was added to the samples before adding the samples to the
chromogenic substrate. Factor Xa or thrombin levels were measured as described in the
Methods section. *P<0.05 vs control.
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Activation of PAR-3 or PAR-4 enhances phosphatidylserine exposure on the surface of
HASMC. HASMC were growth arrested, washed and maintained in reptilase-treated PPP.
Cells were treated with vehicle, α-thrombin (10.7 nM), PAR-1 AP (200 µM), PAR-3 AP
(200 µM), PAR-4 AP (200 µM) or TNF-α (10 ng/ml). Seven minutes after treatment (20
minutes after treatment with TNF-α) the cells were washed, incubated in FITC labeled
Annexin V and washed again. The intensity of the fluorescence signal was measured using
ImageJ (scale bar=50 µM). Representative photomicrographs are shown in A and data from
six independent experiments are shown in B. (*P<0.05 compared to control).
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PAR-3 AP plus PAR-4 AP cause acceleration of HASMC-supported tissue factor–induced
thrombin generation via mechanisms downstream of factor Xa production. HASMCs were
growth arrested, washed, and maintained in reptilase-treated PPP derived from an individual
deficient in factor X. PAR-3 AP (200 µmol/L) plus PAR-4 AP (200 µmol/L), PAR-1 AP
(200 µmol/L), or α-thrombin (1.5 U/mL) was added 15 minutes before nonlipidated tissue
factor, Ca2+ with or without factor Xa (10 pmol/L). Thrombin was assayed at indicated
points, as described in the Methods section. Representative data from 4 independent
experiments are shown.
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